INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2023

In patients with uncontrolled type 2 diabetes, add-on spirulina platensis significantly reduced HbA1c, fasting glucose, and improved lipid profiles.

Sixty patients with uncontrolled type 2 diabetes mellitus were randomized to receive either Spirulina platensis (2 g/day) or placebo for three months alongside usual metformin therapy. Compared to baseline, S. platensis supplementation resulted in significant reductions in HbA1c (decrease of 1.43, p < 0.001) and FBS (decrease of 24.94 mg/dL, p < 0.001). Total cholesterol dropped by 41.36 mg/dL, LDL-C dropped by 38.4 mg/dL, and triglycerides were significantly lower than controls (p < 0.001), while HDL-C showed a marginal increase (increase of 3 mg/dL, p < 0.001). No adverse events were reported.

Study type
Randomized, double-blind, placebo-controlled add-on trial
Who was studied
60 patients with uncontrolled type 2 diabetes mellitus taking metformin
What was measured
HbA1c levels, fasting blood sugar, and lipid profiles (TC, LDL-C, TG, HDL-C)

THE PAPER

A randomized, double-blind placebo-controlled add-on trial to assess the efficacy, safety, and anti-atherogenic effect of spirulina platensis in patients with inadequately controlled type 2 diabetes mellitus.

Karizi SR, Armanmehr F, Azadi HG, Zahroodi HS, Ghalibaf AM, Bazzaz BSF, Abbaspour M, Boskabadi J, Eslami S, Taherzadeh Z. Phytother Res, 2023.

PubMed 36598187 ↗DOI 10.1002/ptr.7674 ↗

Heart & arteriesDiabetes & blood sugar

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.